Drug intelligence / Profile preview

SIM0660 (9b348c)

Development stage: Preclinical
Lead developer: Simcere Pharmaceutical Group
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SIM0660 is an antibody-drug conjugate (ADC) being developed by Simcere Pharmaceutical (specifically through its subsidiary Shandong Simcere Medgenn) for the treatment of oncology indications. The drug specifically targets the Fibroblast Growth Factor Receptor 2b (FGFR2b), a splice variant of FGFR2 that is frequently overexpressed in various epithelial-derived tumors, such as gastric and gastroesophageal junction cancers. As an ADC, SIM0660 is designed to bind to FGFR2b on the surface of cancer cells, undergo internalization, and release a potent cytotoxic payload to induce targeted cell death while sparing healthy tissue.

Targets

FGFR2b (Fibroblast growth factor receptor 2 IIIb isoform)

Beyond the preview

Go deeper on SIM0660 (9b348c).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIM0660 (9b348c).

Explore the full profile